Serojec

Company Overview

Snapshot

Founded in January 2019 by Dr. Daniel Drai, Serojec operates with 1–10 employees. The company has completed a Phase I trial to verify the safety and effectiveness of its drug combination for premature ejaculation.

Business overview

Serojec is a Health Tech & Life Sciences company focused on developing pharmaceutical treatments for premature ejaculation. The company's core technology involves combining existing drugs, specifically a tricyclic antidepressant in low dosage and an alkaloid that relaxes blood vessels. This patented combination aims to neutralize side effects while extending erection duration. Serojec operates within the Pharmaceuticals sector, targeting the broader Healthcare & Life Sciences market.

Strategic signal

In January 2020, Serojec completed a Phase I trial for its premature ejaculation treatment, demonstrating safety and initial signs of effectiveness. This milestone signals the company's progress in clinical development and validates the potential of its patented drug combination, positioning Serojec for further financing or strategic partnerships to advance product development in a significant market.

Company Intelligence Q&A

What is Serojec's primary focus?

Serojec develops patented drug combinations for the treatment of premature ejaculation, aiming to extend erection duration while minimizing side effects.

When was Serojec founded and by whom?

Serojec was founded in January 2019 by Dr. Daniel Drai.

What is the current employee size of Serojec?

Serojec currently has 1–10 employees.

Has Serojec conducted any clinical trials?

Yes, in January 2020, Serojec completed a Phase I trial in cooperation with the University of Vienna, which verified the safety and showed signs of effectiveness for its drug combination.

What is the strategic next step for Serojec following its Phase I trial?

Following the successful Phase I trial in January 2020, Serojec is seeking financing or cooperation with a drug company to further develop its product.